Vaxart secures European patent for oral norovirus vaccine platform
Vaxart has announced that the European Patent Office has formally granted European Patent No. 3791859, covering key aspects of the South San Francisco company's oral recombinant norovirus vaccine candidate and its proprietary pill-based delivery platform. The patent, published on 26 August 2026, extends intellectual property protection across 13 European jurisdictions through at least 2036.
The territories named for validation include Germany, France, Italy, Spain, the United Kingdom, Austria, Belgium, Denmark, Ireland, Netherlands, Norway, Sweden, and Switzerland, representing the bulk of Europe's pharmaceutical market by value.
The technology
Vaxart's platform is built around an adenovirus-vectored oral delivery system that uses TLR3 agonists as an adjuvant. The resulting vaccine is formulated as a pill that is stable at room temperature, removing the cold-chain requirements that complicate distribution of conventional injectable vaccines in lower-resource settings and travel medicine contexts. The norovirus programme is one of four active development tracks at Vaxart, alongside candidates targeting coronavirus, influenza, and human papillomavirus.
Chief executive Steven Lo said the grant "secures our potential advantage in delivering a targeted, oral tablet solution for norovirus, an area of high unmet need," pointing to ongoing challenges facing traditional injected norovirus candidates in the industry. The patent adds to Vaxart's existing domestic and international filings, and the company characterises the expanded European estate as a meaningful strengthening of its commercial position ahead of any eventual regulatory submission.
Market context
Norovirus causes an estimated 685 million cases of gastroenteritis worldwide each year, according to the World Health Organisation, and is responsible for significant morbidity in hospital, cruise, and care-home settings. Despite this burden, no approved norovirus vaccine currently exists anywhere in the world, making the space genuinely open for first-movers.
Vaxart is not the only company pursuing the indication. Moderna has reported Phase 2 data on an mRNA-based norovirus candidate, and HilleVax, a spin-out from Takeda's norovirus programme, has advanced its virus-like particle vaccine into Phase 3. Both candidates are injectable, which Vaxart argues reinforces the differentiation of its oral, cold-chain-free approach.
The broader oral vaccine space has seen renewed investor and public-health interest following the COVID-19 pandemic, which exposed distribution vulnerabilities in injection-dependent immunisation programmes. Regulatory agencies including the EMA have signalled openness to novel delivery modalities, provided immunogenicity and safety data are robust.
For Vaxart, the patent grant is primarily a defensive and commercial milestone rather than a clinical one. The company has not disclosed a current Phase 2 or Phase 3 timeline for its norovirus programme in Europe, and near-term attention will focus on its US clinical activities and cash position. The OTCQX-listed company has historically relied on equity raises and partnership agreements to fund operations, and investors will be watching for any indication of a European development or commercialisation partner as the IP estate matures.